Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AERase/AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AECase/AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies. The company also engages in developing AEMase/AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. It has a strategic partnership with KBI Biopharma. Aeglea Biotherapeutics, Inc. was formerly known as Aeglea BioTherapeutics Holdings, LLC. The company was founded in 2013 and is based in Austin, Texas.

Aeglea Bio Therapeutics Inc

Aeglea Biotherapeutics, Inc. operates as a biopharmaceutical company, which engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies; AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. The company was founded in December 13, by by George Georgiou and David G. Lowe and is headquartered in Austin, TX.

Aeglea Bio Therapeutics Inc (AGLE) : Buy or Sell